To the best of our knowledge, using various anti-MGMT antibodies and applying diverse criteria for MGMT immunopositivity, immunohistochemical studies concerning MGMT protein expression in breast cancer have demonstrated that 54–81% of breast cancers are MGMT-positive (8,12–14,25,26). This evidence concerns the gene MGMT and breast carcinoma.